Skip to main content
RYVU Therapeutics S.A. logo

RYVU Therapeutics S.A. — Investor Relations & Filings

Ticker · RVU ISIN · PLSELVT00013 LEI · 2594003WO9Q9HHAFL031 WAR Professional, scientific and technical activities
Open in API
Filings indexed 803 across all filing types
Latest filing 2026-04-21 Regulatory Filings
Country PL Poland
Listing WAR RVU

About RYVU Therapeutics S.A.

https://ryvu.com/

Ryvu Therapeutics is a clinical-stage drug discovery and development company specializing in novel small molecule therapies for oncology. The company's research focuses on emerging biological targets and pathways, including kinase inhibition, synthetic lethality, and immuno-oncology, to develop precise cancer treatments. Its pipeline features several candidates in various stages of development. Key clinical-stage assets include Romaciclib (RVU120), a selective CDK8/19 kinase inhibitor for treating hematologic malignancies like acute myeloid leukemia (AML) and myelofibrosis, and Dapolsertib (MEN1703), a PIM/FLT3 inhibitor. The company also advances preclinical programs, such as an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP deletion.

Recent filings

Filing Released Lang Actions
Poster dotyczący danych przedklinicznych dla platformy ONCO Prime zaprezentowany na dorocznym zjeździe AACR 2026 / Poster presenting preclinical data for the ONCO Prime platform at the AACR Annual ...
Regulatory Filings Classification · 1% confidence The document is a brief current report by a listed company (Ryvu Therapeutics) announcing the presentation of preclinical data at an external scientific conference (AACR Annual Meeting). It is not an annual or interim financial report, earnings release, management change, dividend announcement, M&A, or other defined category. It serves as a regulatory announcement of business activities and is filed as a current report. Thus, it falls under the fallback category “Regulatory Filings” (RNS).
2026-04-21 English
Poster dotyczący danych przedklinicznych dla platformy ONCO Prime zaprezentowany na dorocznym zjeździe AACR 2026 / Poster presenting preclinical data for the ONCO Prime platform at the AACR Annual ...
Regulatory Filings Classification · 1% confidence The document is a current report (“raport bieżący”) informing the market that Ryvu Therapeutics presented preclinical data at the AACR conference via a poster. It is not a financial earnings release, management change, proxy or dividend announcement, or any formal report like an Annual or Interim report. It is a general corporate announcement filed with the regulator, so it falls under the fallback category “Regulatory Filings” (RNS).
2026-04-21 Polish
Notyfikacja Vatnak Vat-Ho
Director's Dealing Classification · 1% confidence The document is a notification under Article 19(1) of the Market Abuse Regulation (MAR) detailing personal share transactions by a Member of the Management Board. It lists the insider’s name, role, LEI, instrument identification, transaction types (disposals), dates, prices, volumes, and trading venue. This matches the definition of Director’s Dealing (reports of personal share transactions by company directors/executives).
2026-04-14 English
Powiadomienie od osoby pełniącej obowiązki zarządcze w Spółce - art. 19 MAR / Notification from a person discharging managerial responsibilities in the Company - Article 19 MAR - Content (EN)
Director's Dealing Classification · 1% confidence The document is a notification of a share transaction by a Member of the Management Board (person discharging managerial responsibilities) under Article 19 MAR, detailing pre- and post-transaction holdings. This fits the Director's Dealing category.
2026-04-14 English
Powiadomienie od osoby pełniącej obowiązki zarządcze w Spółce - art. 19 MAR / Notification from a person discharging managerial responsibilities in the Company - Article 19 MAR - Content (PL)
Director's Dealing Classification · 1% confidence The document is a notification under Article 19 MAR of a management board member’s personal sale of company shares, detailing before and after holdings. This matches the definition of a Director’s Dealing (insider transaction by a director).
2026-04-14 Polish
Sprawozdanie biegłego rewidenta z badania 2025
Regulatory Filings
2026-03-19 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.